Loading…
Cellyan Biotechnology Co., Ltd is projected to decline to $0.4003 by 2027, a -11% move from its current price of $0.45. HKPD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.4241 | $0.4496 | $0.4766 | -0.09% |
| Jul 14 | $0.4136 | $0.4492 | $0.4878 | -0.18% |
| Jul 15 | $0.4057 | $0.4488 | $0.4965 | -0.27% |
| Jul 16 | $0.399 | $0.4484 | $0.5039 | -0.36% |
| Jul 17 | $0.3932 | $0.448 | $0.5104 | -0.44% |
| Jul 18 | $0.388 | $0.4476 | $0.5164 | -0.53% |
| Jul 19 | $0.3832 | $0.4472 | $0.5218 | -0.62% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3832 | $0.4472 | $0.5218 | -0.62% |
| Week 2 | $0.3573 | $0.4444 | $0.5528 | -1.24% |
| Week 3 | $0.3381 | $0.4417 | $0.577 | -1.85% |
| Week 4 | $0.3224 | $0.4389 | $0.5976 | -2.46% |
| Week 5 | $0.3089 | $0.4362 | $0.616 | -3.07% |
| Week 6 | $0.297 | $0.4335 | $0.6326 | -3.67% |
| Week 7 | $0.2864 | $0.4308 | $0.648 | -4.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellyan Biotechnology Co., Ltd is an investment holding company that engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. It provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services.
It also offers customs clearance, drugs enlistment, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors.
The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
The asset trades under the symbol HKPD and is categorized in Healthcare. The current price is $0.4396.
Its market capitalization is $10.33M and it ranks 4978 by market cap. This places it among smaller-cap healthcare equities with notable volatility implied by the forecasted path ahead.
The overall price outlook is mixed, with a year-by-year forecast showing periods of decline and periods of growth. The 2026 average price is $0.4396, and the forecast spans through 2050 with varying highs and lows, including bear moves in the late 2020s and bullish turns in the 2030s–2050s, with a max forecast of $2.06 and a long-run average around $0.894 for 2050.
A major floor 49.5% below — a decisive break under it would weaken the trend.
The nearest floor, 26.0% below — buyers have tended to step in here.
The nearest ceiling, 22.2% above — a clean break opens room to run.
A major ceiling 62.2% above — clearing it would confirm fresh momentum.
Key HKPD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HKPD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.4448 | Buy | $0.4401 | Buy |
| MA 10 | $0.417 | Buy | $0.4282 | Buy |
| MA 20 | $0.411 | Buy | $0.4311 | Buy |
| MA 50 | $0.5005 | Sell | $0.4869 | Sell |
| MA 100 | $0.5712 | Sell | $0.5815 | Sell |
| MA 200 | $0.7965 | Sell | $0.7837 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.21 | Neutral |
| Stoch RSI (14) | 90.40 | Sell |
| CCI (20) | 79.53 | Neutral |
| Williams %R (14) | -12.39 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 25.00 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 87.61 | Sell |
| TRIX (15) | -0.95 | Sell |
| Awesome (5,34) | -0.01 | Sell |
| Ultimate (7,14,28) | 65.44 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 0.45 | Sell |
| ADX (14) | 15.01 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 50. This suggests balanced momentum with no immediate overbought or oversold pressure.
Price is near the SMA50 of $0.5214 while trading below the SMA200 of $0.8189, indicating a cautious near-term stance. The near-term path may hinge on whether price holds the $0.333 support or breaks toward resistance at $0.55.
The 30-day price range spans from a low of $0.2893 to a high of $0.6681, underscoring notable short-term volatility. Annualized volatility is listed at 100% in the data.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.333 | $0.45 | $0.5309 | 0% | Neutral | |
| $0.2904 | $0.4003 | $0.5967 | -11% | Neutral | |
| $0.2776 | $0.4066 | $0.6458 | -10% | Neutral | |
| $0.2021 | $0.3118 | $0.5199 | -31% | Bearish | |
| $0.2312 | $0.3741 | $0.6493 | -17% | Bearish | |
| $0.2943 | $0.4976 | $0.8941 | +11% | Neutral | |
| $0.3044 | $0.5369 | $0.9945 | +19% | Neutral | |
| $0.2991 | $0.5492 | $1.05 | +22% | Bullish | |
| $0.2451 | $0.4682 | $0.9141 | +4% | Neutral | |
| $0.2244 | $0.4457 | $0.8902 | -1% | Neutral | |
| $0.3279 | $0.7288 | $1.60 | +62% | Bullish | |
| $0.4342 | $0.9648 | $2.22 | +114% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.333 | $0.45 | $0.5655 | +0.00% |
| August 2026 | $0.365 | $0.4423 | $0.5584 | -1.71% |
| September 2026 | $0.3376 | $0.4149 | $0.5347 | -6.20% |
| October 2026 | $0.3386 | $0.4212 | $0.5522 | +1.51% |
| November 2026 | $0.3352 | $0.4213 | $0.5603 | +0.02% |
| December 2026 | $0.3104 | $0.394 | $0.5309 | -6.49% |
Click any year to see its month-by-month HKPD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cellyan Biotechnology Co., Ltd's 2026 outlook centres on $0.45, within a $0.333 to $0.5309 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, HKPD could reach as high as $0.5967, with a base case around $0.4003 and support toward $0.2904 — roughly -11% from $0.45. A consolidation phase looks the most probable path here.
Expect HKPD to range from $0.2776 to $0.6458 through 2028. The $0.4066 average target implies a -10% move from current prices. That is up +2% on the projected 2027 average. Price action looks broadly range-bound.
The HKPD price prediction for 2029 points to an average of $0.3118 (low $0.2021, high $0.5199) — a potential decline of -31% on today's $0.45. Expect choppier, lower action through this leg of the cycle.
In 2030, HKPD is projected to trade between $0.2312 and $0.6493, averaging $0.3741 — a potential decline of -17% from today's $0.45. That is up +20% on the projected 2029 average. A cyclical pullback looks likely — prices rarely move in a straight line.
Cellyan Biotechnology Co., Ltd's 2031 outlook centres on $0.4976, within a $0.2943 to $0.8941 range. That is up +33% on the projected 2030 average. That marks a +11% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, HKPD could reach as high as $0.9945, with a base case around $0.5369 and support toward $0.3044 — roughly +19% from $0.45. Price action looks broadly range-bound.
Expect HKPD to range from $0.2991 to $1.05 through 2033. The $0.5492 average target implies a +22% move from current prices. That is up +2% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The HKPD price prediction for 2034 points to an average of $0.4682 (low $0.2451, high $0.9141) — a potential gain of +4% on today's $0.45. Price action looks broadly range-bound.
In 2035, HKPD is projected to trade between $0.2244 and $0.8902, averaging $0.4457 — a potential decline of -1% from today's $0.45. That is -5% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Cellyan Biotechnology Co., Ltd's 2040 outlook centres on $0.7288, within a $0.3279 to $1.60 range. That is up +64% on the projected 2035 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2050, HKPD could reach as high as $2.22, with a base case around $0.9648 and support toward $0.4342 — roughly +114% from $0.45. Buyers look set to stay in control over this stretch.
Investing $1,000 in HKPD today (≈ 2,222.222222 HKPD) could be worth
$2,144
+$1,144 (+114%) by 2050 · US Dollar
Based on the average projected HKPD price of $0.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HKPDwould be worth at today's price.
$1,000 invested in HKPD on Jul 10, 2025 (≈ 735.29411 HKPD) would be worth
$330.88
-$669.12 (-66.9%) today · 0.33× · US Dollar
Based on a HKPD entry price of $1.36 vs. today's $0.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.44 | $1,022.73 | +2.3% |
| 1 month ago | $0.45 | $1,000 | +0.0% |
| 3 months ago | $0.622 | $723.47 | -27.7% |
| 6 months ago | $0.799 | $563.2 | -43.7% |
| 1 year ago | $1.36 | $330.88 | -66.9% |
| All time (1.5y) ago | $2.82 | $159.57 | -84.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HKPD forecast.
Our base-case forecast reaches $0.90 around 2050.
Implied market cap at $0.90: $14.71M
The multi-year forecast shows a fluctuating path from 2026 through 2050. In 2026 the average price is $0.4396 with a neutral sentiment and a 0% ROI; the 2027 average is $0.3973 with a -9.6% ROI, and 2028 averages $0.3938 with a -10.4% ROI.
The forecast continues to show weakness in 2029 (average $0.2936, ROI -33.2%) and 2030 (average $0.3631, ROI -17.4%), before stabilizing into neutral territory in 2031 ($0.4756, ROI 8.2) and 2032 ($0.5078, ROI 15.5).
2033 marks a bullish turn, with an average of $0.5323 and ROI 21.1%. The year 2034 remains neutral at $0.4457 (ROI 1.4) and 2035 stays neutral at $0.4214 (ROI -4.1%). By 2040 the forecast turns strongly bullish, with an average of $0.6839 and ROI 55.6% (max $1.50).
The long-run path remains positive into 2050, with an average of $0.894 and ROI 103.4% (max $2.06).
Overall, the upside potential appears in the later years (2040 and 2050), but the path includes earlier bear phases (notably 2029–2030) and mixed sentiment in the intervening years. These are estimates, not guarantees, and reflect the provided forecast figures.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $0.2242, an average of $0.3631, and a max of $0.6307, with a ROI of -17.4% and Bearish sentiment.
Forecasts show mixed results: bear phases in 2029 and 2030 with negative ROI, followed by improvements later in the decade and into the 2030s. Notably, 2033 has an average of $0.5323 with ROI 21.1% (Bullish), 2040 has ROI 55.6% (avg $0.6839), and 2050 has ROI 103.4% (avg $0.894), indicating potential upside but with substantial variability.
Yes. The forecast maximum for 2033 is $1.01, indicating a potential to surpass $1.00 in that year, though this is not guaranteed.
The 2040 forecast shows an average price of $0.6839 with a maximum of $1.50 and a bullish sentiment.
The 2050 forecast shows an average price of $0.894 with a maximum of $2.06 and a bullish sentiment, corresponding to an ROI of 103.4%.
Cellyan Biotechnology Co., Ltd Community Discussion
0Share your Cellyan Biotechnology Co., Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.